Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
J. Cortes, R. Digumarti, P. M. Parikh, M. Wetzler, J. H. Lipton, A. Hochhaus, A. R. Craig, A. C. Benichou, F. E. Nicolini, H. M. Kantarjian
Research output: Contribution to journal › Article › peer-review
Dive into the research topics of 'Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors'. Together they form a unique fingerprint.